SURVYR

IVA

Inventiva S.A.
$3.71
+$0.03 (0.68%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-59%-40%-22%-3%+16%Oct 2025Oct 2026Apr 202652w high $7.9852w low $2.82
IVASPY
Wall St. Highest PT $26.00 (+600.8%) Wall St. Avg PT $15.20 (+309.7%)
$3$11$19$27$36POC $5Hi $26Avg $15
Underwater Drawdown %Max DD -59.9%Current -48.1%
0.0%-59.9%
Relative Strength vs SPY-60.2% vs SPYUnderperforming
+84%0%-84%
1W
+$0.16 (4.51%)
1M
+$0.18 (5.10%)
3M
−$0.80 (17.74%)
6M
−$1.23 (24.90%)
YTD
−$0.94 (20.22%)
1Y
−$1.56 (29.60%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
10 analysts · mean score 1.08
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$3.71
Average target$15.20
+$11.49 (+309.7%) upsideaverage target vs current price
CurrentAverageMedian
Low$10.00
Median$15.20
High$26.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-10-02 · Truist Securities reiterated Buy on IVA
Reiterated
2026-09-29 · Canaccord Genuity reiterated Buy on IVA
Reiterated
2026-09-15 · Guggenheim reiterated Buy on IVA
Initiated
2026-07-17 · Cantor Fitzgerald started covering IVA at Overweight
Initiated
2026-03-19 · Truist Securities started covering IVA at Buy
Initiated
2026-01-28 · Barclays started covering IVA at Overweight
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$836.2M
P/E (next 12 months, estimated)-4.8
52-week range$2.82 – $7.98
Revenue growth (latest quarter vs a year ago)-76.7%
Dividend yieldNo dividend
Analyst consensusStrong Buy (10)
Average analyst price target$15.20 (+310%)

What they do

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for IVA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

IVA earningsNext report in 155 days
Next report
Thu Apr 1, 2027After the close
EPS consensus–
Revenue consensus$0 2 analysts
Last 3 quarters · EPS vs estimate
Mar 10, 2022-$0.16est -$0.39+58.2%Above estimates
Mar 10, 2022-$0.16est -$0.48+65.7%Above estimates
Sep 16, 2020-$0.21est -$0.45+52.3%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 11:24:13 ET
20-0922-0322-03-0.480.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
MarketBeat · Oct 10
Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026
GlobeNewswire · Oct 06
Inventiva (IVA): How Much Is One Make-or-Break Readout Really Worth?
Insider Monkey · Oct 04
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
MarketBeat · Oct 04
Truist Raises Price Target on Inventiva to $18 From $13, Keeps Buy Rating
MT Newswires · Oct 02
Rating changes
Reiterated
2026-10-02 · Truist Securities reiterated Buy on IVA
Reiterated
2026-09-29 · Canaccord Genuity reiterated Buy on IVA
Reiterated
2026-09-15 · Guggenheim reiterated Buy on IVA
Initiated
2026-07-17 · Cantor Fitzgerald started covering IVA at Overweight
Initiated
2026-03-19 · Truist Securities started covering IVA at Buy
Initiated
2026-01-28 · Barclays started covering IVA at Overweight

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 11:24:13 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026